Efficacy of re-irradiation with carbon ions (RiCi) in patients with recurrent high-grade glioma (rHGG) compared to the standard re-irradiation with photons (RiP): The reference multicenter cohort of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG).

Author:

Knoll Maximilian1,Waltenberger Maria2,Bougatf Nina1,Bernhardt Denise2,Adeberg Sebastian2,Budach Volker3,Baumann Michael4,Stuschke Martin5,Fokas Emmanouil6,Grosu Anca7,Zips Daniel8,Belka Claus9,Combs Stephanie E10,von Deimling Andreas11,Bendszus Martin12,Wick Wolfgang12,Unterberg Andreas13,Rieken Stefan2,Debus Juergen2,Abdollahi Amir2

Affiliation:

1. Departments of Radiation Oncology, Neurology, Neurosurgery, Heidelberg University Hospital, National Center for Tumor Disease (NCT), UKHD and German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), Core-Center Heidelberg, Heidelberg, Germany;

2. Heidelberg Ion-Beam Therapy Center (HIT), Department of Radiation Oncology, Heidelberg University Hospital (UKHD), National Center for Tumor Diseases (NCT), UKHD and German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK) Core Center Heidelb, Heidelberg, Germany;

3. German Cancer Consortium (DKTK) Core Center Heidelberg and DKTK Partner Site Berlin, Berlin, Germany;

4. National Center for Tumor Diseases (NCT), UKHD and German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK) Core Center Heidelberg, Heidelberg, Germany;

5. German Cancer Consortium (DKTK) Core Center Heidelberg and DKTK Partner Site Essen, Essen, Germany;

6. German Cancer Consortium (DKTK) Core Center Heidelberg and DKTK Partner Site Frankfurt, Oxford, United Kingdom;

7. German Cancer Consortium (DKTK) Core Center Heidelberg and DKTK Partner Site Freiburg, Freiburg, Germany;

8. German Cancer Consortium (DKTK) Core Center Heidelberg and DKTK Partner Site Tübingen, Tübingen, Germany;

9. German Cancer Consortium (DKTK) Core Center Heidelberg and DKTK Partner Site Munich, Munich, Germany;

10. German Cancer Consortium (DKTK) Core Center Heidelberg and DKTK Partner Site Munich (TUM), Munich, Germany;

11. Department of Neuropathology, Institute of Pathology, Heidelberg University Hospital (UKHD), National Center for Tumor Diseases (NCT), UKHD and German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK) Core Center Heidelberg, Germany, Heidelberg, Germany;

12. National Center for Tumor Diseases (NCT), UKHD and German Cancer Research Center (DKFZ), Heidelberg, Germany;

13. Departments of Radiation Oncology, Neurology, Neurosurgery, Heidelberg University Hospital, National Center for Tumor Disease (NCT), UKHD and German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), Core-Center Heidelberg, GermanyNational Ce, Heidelberg, Germany;

Abstract

2057 Background: Local recurrence after surgery and radio(chemo)therapy remains a major obstacle in curative treatment of patients with HGG. Eradication of radioresistant glioma subpopulations (hypoxic- and stem cell like cells) together with formation of an antiangiogenic and immuno-permissive glioma niche are among beneficial radiobiological effects recently attributed to carbon ion irradiation in preclinical models. The impact of this novel therapy in management of rHGG patients remains elusive. Methods: 197 patients with rHGG (grade III: 71, IV: 126) received RiCi between Nov 2009 and Feb 2018 at HIT with a median dose of 42GyRBE in 14 fractions. In DKTK-ROG multicenter cohort n:565 rHGG patients (grade III: 63, IV: 479) underwent RiP between 1997-2016 with a median dose of 36 Gy in 14 fractions. Median follow up was 34.2 months (M) for RiCi and 7.1 M for RiP (DKTK) cohort. All three prognostic scores validated in DKTK-ROG cohort were evaluated and re-irradiation risk score (RRRS) considering initial grade, Karnofsky Performance Score and age at re-irradiation was utilized for stratification and matched comparisons. Results: Median PFS was 5.08 [4.26-5.87] M (grade III: 6.79, grade IV: 3.64) after RiCi, data was not available for RiP. Median OS was 10.52 [9.28-12.66] M (grade III: 28.2, grade IV: 8.53) after RiCi compared to 7.93 [7.15-8.79] M (grade III: 10.89, grade IV: 7.93) after RiP. Among the three prognostic scores evaluated, RRRS most robustly correlated with OS. RiCi was associated with HR of 0.52 ([0.49-0.72], p = 0.0000002), and HR 0.66 ([0.51-0.85], p = 0.001) for RRRS matched analysis. Conclusions: Carbon ions demonstrated activity in rHGG. This effect is most prominent in grade III while grade IV patients may further benefit from innovative multimodal strategies. Based on these encouraging results prospective randomized trials utilizing RRRS for stratification are recommended.

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3